Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $15.46 USD
Change Today +0.45 / 3.00%
Volume 142.9K
SGNT On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

sagent pharmaceuticals inc (SGNT) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/19/15 - $30.75
52 Week Low
11/24/15 - $13.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sagent pharmaceuticals inc (SGNT) Related Businessweek News

No Related Businessweek News Found

sagent pharmaceuticals inc (SGNT) Details

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, and pyelonephritis in adults of age 18 years or older. It also provides oncology products consisting of Leucovorin Calcium, a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer; and Zoledronic Acid, a bisphosphonate given intravenously to prevent skeletal fractures in patients with cancers, such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. In addition, the company offers critical care products comprising Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis; and Propofol, a sedative used to induce and maintain general anesthesia during surgical procedures. As of December 31, 2014, its product portfolio included 54 marketed products. Sagent Pharmaceuticals, Inc. sells its products to hospitals, integrated delivery networks, and alternative site facilities through pharmaceutical wholesalers and specialty distributors. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.

466 Employees
Last Reported Date: 03/16/15
Founded in 2006

sagent pharmaceuticals inc (SGNT) Top Compensated Officers

President, Chief Legal Officer and Corporate ...
Total Annual Compensation: $328.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $344.8K
Executive Vice President of National Accounts...
Total Annual Compensation: $297.1K
Compensation as of Fiscal Year 2014.

sagent pharmaceuticals inc (SGNT) Key Developments

Sagent Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Reaffirms Earnings Guidance for the Year Ending December 31, 2015

Sagent Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. Net revenue for the third quarter of 2015 was $75.2 million, an increase of $9.8 million, or 15%, compared to $65.4 million in the third quarter of 2014.  The increase was driven by the $7.3 million from the addition of Omega on October 1, 2014 and the contribution from the launch of new products since September 30, 2014. Adjusted EBITDA for the third quarter of 2015 was $8.8 million, an increase of $1.5 million, or 21% compared to $7.2 million in the third quarter of 2014. The increase in adjusted EBITDA is primarily driven by the increase in adjusted gross profit, offset by the increase in product development expense due to the timing of milestone payments. The net loss for the three months ended September 30, 2015 was $1.8 million, compared to net income of $1.9 million in the third quarter of 2014. EBITDA was $2.681 million against $5.173 million a year ago. The company reported income from operations of $1.742 million compared to $4.044 million, loss before income taxes of $0.132 million compared to profit before income taxes of $3.313 million, net loss of $1.795 million or $0.05 per diluted share compared to net income $1.926 million or $0.06 per diluted share. For the nine months, the company reported revenue of $235.188 million compared to $205.422 million, income from operations of $2.743 million compared to $13.994 million, Loss before income taxes of $0.132 million compared to profit before income taxes of $12.888 million, net loss of $3.945 million or $0.12 per diluted share compared to net income of $10.114 million or $0.31 per diluted share and adjusted EBITDA of $24.058 million compared to $23.956 million for the last year. EBITDA was $9.183 million against $19.427 million a year ago. For the year ending December 31, 2015, the company expects net revenue for the year to be in the range of $305 to $330 million; adjusted gross profit as a percentage of net revenue in the range of 25% to 28%; and operating expenses in the range of $80 to $90 million. Based on the above assumptions, the company anticipates adjusted EBITDA in the range of $20 - $30 million. EBITDA expected to be in the range of $10 to $18 million. Depreciation and amortization expense are expected to be in the range of $12 to $16 million.

Sagent Pharmaceuticals Introduces Chlorothiazide Sodium for Injection

Sagent Pharmaceuticals announced that it has introduced Chlorothiazide Sodium for Injection, USP, a diuretic/antihypertensive agent, in a 500 mg preservative-free, single-dose vial. The product features the company's PreventIV MeasuresSM Packaging and Labelling, aimed at helping decrease the risk of medication errors. The product is indicated as an adjunctive therapy in oedema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.

Sagent Pharmaceuticals, Inc. to Report Q3, 2015 Results on Nov 03, 2015

Sagent Pharmaceuticals, Inc. announced that they will report Q3, 2015 results at 9:00 AM, US Eastern Standard Time on Nov 03, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $15.46 USD +0.45

SGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $15.47 USD +0.62
OraSure Technologies Inc $6.25 USD +0.03
Pernix Therapeutics Holdings Inc $3.03 USD +0.02
SciClone Pharmaceuticals Inc $9.25 USD +0.08
Sucampo Pharmaceuticals Inc $18.22 USD +0.13
View Industry Companies

Industry Analysis


Industry Average

Valuation SGNT Industry Range
Price/Earnings 19.4x
Price/Sales 1.6x
Price/Book 1.9x
Price/Cash Flow 19.6x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SAGENT PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at